FemCap Barrier Contraceptive To Launch In May; Licensing Partner Sought
This article was originally published in The Gray Sheet
Executive SummaryFemCap, Inc. is seeking to license its female barrier contraceptive to potential marketing partners to facilitate broad adoption of the product
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.